Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas

Launched by INSTITUT DU CANCER DE MONTPELLIER - VAL D'AURELLE · Jan 8, 2020

Keywords

ClinConnect Summary

This clinical trial is focused on finding a new and easier way to diagnose liposarcomas, a type of cancer that occurs in fat tissue. The researchers want to develop a blood test that measures specific levels of a substance called serine, which could help identify this cancer without needing more invasive procedures like biopsies. Currently, doctors usually confirm the diagnosis by looking for changes in certain genes, which can be more complex.

To participate in this study, you need to be at least 18 years old and have been diagnosed with localized or recurrent liposarcoma or have a large tumor suggestive of an atypical lipomatous tumor. Healthy individuals over 18 who match the age and sex of the patients are also welcomed to join. Participants will provide blood samples, and everyone will need to give their consent to take part. This trial is currently recruiting, so if you're interested, you could help advance research that may lead to a simpler way to diagnose liposarcoma in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria for LPS patients cohort:
• • Men/women older than 18 years old,
• Surgery for :
• • Localized WD-LPS and DD-LPS, and/or
• • WD-LPS or DD-LPS local relapse, and/or
• • WD-LPS or DD-LPS distant relapse and/or
• • Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent
• Inclusion Criteria for healthy subjects cohort:
• • Men/women older than 18 years old, Accepting blood sample, Who signed informed consent Matching on sex and age on LPS patient cohort
• Exclusion Criteria:
• • Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma.
• • Pregnancy and/or feeding